Literature DB >> 2081486

Mechanisms of NSAID-induced gastroenteropathy.

A H Price1, M Fletcher.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used and therapeutically effective groups of drugs in the Western world. However, gastrointestinal problems constitute all too frequently reported unwanted effects of NSAIDs; their effects on the gastric (and intestinal) mucosa are, therefore, well documented. A review of the evidence suggests that NSAID-induced gastric damage occurs as a result of a dual insult, by NSAID-mediated direct (and indirect) acidic damage followed almost simultaneously by the deleterious (systemic) effect of prostaglandin inhibition. A number of strategies have been used in the management of NSAID-induced gastric damage; however, not all have been entirely successful. Nonetheless, a number of approaches have met with a considerable amount of success, including direct gastroprotection, enhancement of mucosal defence mechanisms and, perhaps most encouragingly, the development of newer NSAIDs which display not only considerable clinical efficacy but a reduced gastrointestinal adverse event profile.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081486     DOI: 10.2165/00003495-199000405-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  49 in total

1.  Investigation of the vasodilator and antisecretory role of prostaglandins in the rat gastric mucosa by use of non-steroidal anti-inflammatory drugs.

Authors:  I H Main; B J Whittle
Journal:  Br J Pharmacol       Date:  1975-02       Impact factor: 8.739

2.  A pharmacokinetic approach to the understanding of therapeutic effects and side effects of salicylates.

Authors:  K Brune; P Graf; K D Rainsford
Journal:  Agents Actions Suppl       Date:  1977

3.  Ranitidine effect on gastric mucosa damage in patients with rheumatoid diseases on long-term treatment with non-steroid anti-inflammatory drugs.

Authors:  J Piotrowski; A Gabryelewicz; S Konturek; N Kwiecień; G Rydzewska; S Sierakowski; L Zimnoch
Journal:  Mater Med Pol       Date:  1986 Jul-Sep

4.  Gastric ulcerogenicity of non-steroidal anti-inflammatory drugs in mice with mucosa sensitized by cholinomimetic treatment.

Authors:  K D Rainsford
Journal:  J Pharm Pharmacol       Date:  1987-08       Impact factor: 3.765

Review 5.  Gastric mucosal blood flow: its measurement and importance in mucosal defense mechanisms.

Authors:  L Y Cheung
Journal:  J Surg Res       Date:  1984-03       Impact factor: 2.192

6.  Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach.

Authors:  B A Hills; B D Butler; L M Lichtenberger
Journal:  Am J Physiol       Date:  1983-05

7.  Effect of indomethacin on gastric mucosal prostaglandins in humans. Correlation with mucosal damage.

Authors:  J S Redfern; E Lee; M Feldman
Journal:  Gastroenterology       Date:  1987-04       Impact factor: 22.682

8.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.

Authors:  C P Armstrong; A L Blower
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

Review 9.  Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs.

Authors:  K D Rainsford
Journal:  Scand J Gastroenterol Suppl       Date:  1989

10.  Effect of 16,16-dimethyl prostaglandin E2 on the surface hydrophobicity of aspirin-treated canine gastric mucosa.

Authors:  L M Lichtenberger; J E Richards; B A Hills
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

View more
  9 in total

Review 1.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

2.  Effects of chronic treatment with indomethacin at clinically relevant doses on intestinal tissue 6-keto prostaglandin F1 alpha and leukotriene B4 level in relation to gastroenteropathy.

Authors:  A Uçar; S D Sak; M Melli
Journal:  Inflammation       Date:  1998-06       Impact factor: 4.092

3.  The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.

Authors:  U Busch; G Heinzel; H Narjes
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

5.  Acrylic acid-methyl methacrylate (2.5:7.5/2:8) enteric copolymer for colon targeted drug delivery.

Authors:  Saurabh Vijay; O P Sati; Dipak K Majumdar
Journal:  J Mater Sci Mater Med       Date:  2010-12-05       Impact factor: 3.896

6.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

7.  The impact of recent data on our understanding of the roles of COX-1 and COX-2 in gastrointestinal pathophysiology.

Authors:  Ingvar Bjarnason
Journal:  Clin Drug Investig       Date:  2007-12       Impact factor: 2.859

8.  Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen.

Authors:  V K Tammara; M M Narurkar; A M Crider; M A Khan
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

Review 9.  A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain.

Authors:  L S Nuutinen; J O Laitinen; T E Salomäki
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.